AR108217A1 - ADDRESSING LINKS CONSTITUTED BY OLIGOMERIC COMPOUNDS - Google Patents
ADDRESSING LINKS CONSTITUTED BY OLIGOMERIC COMPOUNDSInfo
- Publication number
- AR108217A1 AR108217A1 ARP170100567A ARP170100567A AR108217A1 AR 108217 A1 AR108217 A1 AR 108217A1 AR P170100567 A ARP170100567 A AR P170100567A AR P170100567 A ARP170100567 A AR P170100567A AR 108217 A1 AR108217 A1 AR 108217A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- oligomeric compounds
- expression
- therapeutic
- targeting ligands
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen ligandos de direccionamiento que se pueden unir a compuestos, como compuestos terapéuticos útiles para dirigir los compuestos a la diana in vivo. Los ligandos de direccionamiento divulgados en la presente pueden servir para dirigir los compuestos oligoméricos que inhiben la expresión, como agentes de ARNi, a células hepáticas para modular la expresión génica. Los ligandos de direccionamiento divulgados en la presente, al conjugarse a un compuesto terapéutico, se pueden usar en una variedad de aplicaciones, incluyendo el uso en aplicaciones terapéuticas, de diagnóstico, validación de diana y descubrimiento genómico. Las composiciones que incluyen los ligandos de direccionamiento divulgados en la presente, al unirse a compuestos oligoméricos que inhiben la expresión, son capaces de mediar la expresión de secuencias de ácido nucleico diana en células hepáticas, como hepatocitos, que pueden ser útiles en el tratamiento de enfermedades o afecciones que responden a la inhibición de la expresión génica o la actividad en una célula, tejido u organismo.Addressing ligands that can be bound to compounds are described as therapeutic compounds useful for directing the compounds to the target in vivo. The targeting ligands disclosed herein may serve to direct oligomeric compounds that inhibit expression, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to a therapeutic compound, can be used in a variety of applications, including use in therapeutic, diagnostic, target validation and genomic discovery applications. Compositions that include the targeting ligands disclosed herein, by binding to oligomeric compounds that inhibit expression, are capable of mediating the expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to the inhibition of gene expression or activity in a cell, tissue or organism.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383221P | 2016-09-02 | 2016-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108217A1 true AR108217A1 (en) | 2018-08-01 |
Family
ID=63312468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100567A AR108217A1 (en) | 2016-09-02 | 2017-03-07 | ADDRESSING LINKS CONSTITUTED BY OLIGOMERIC COMPOUNDS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR108217A1 (en) |
-
2017
- 2017-03-07 AR ARP170100567A patent/AR108217A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210207A1 (en) | Targeting Ligands | |
| JOP20210231A1 (en) | Targeting Ligands For Therapeutic Compounds | |
| CY1123693T1 (en) | RNAI AGENTS, COMPOSITIONS AND METHODS OF USING THEREOF FOR THE THERAPEUTIC TREATMENT OF TRANSTHYRETIN (TTR)-RELATED DISEASES | |
| PH12019502333A1 (en) | Targeted compositions | |
| CL2018000803A1 (en) | Compositions and methods to inhibit lpa gene expression. | |
| BR112017007765A2 (en) | adenosine deaminase-2 (ada2) compositions, variants thereof and methods of using it | |
| CY1118695T1 (en) | SUSPENSIONS OF STONES | |
| BR112016002496A2 (en) | compound of formula i, pharmaceutical composition, method for inhibiting kdm1a, method for treating a globin-mediated disease, method for achieving an effect on a patient, and method for inhibiting at least one function of kdm1a | |
| BR112018070956A2 (en) | compounds of the formula, pharmaceutical compositions and methods for delivering a nucleic acid to an animal's liver and for preparing a compound of the formula | |
| UY29639A1 (en) | AMIDAS REPLACED WITH HETEROARILO UNDERSTANDING AN INSATURED OR CYCLIC LINKER GROUP, AND ITS USE AS PHARMACEUTICAL PRODUCTS | |
| UY31384A1 (en) | NEW HETEROCICLIC COMPOUNDS FOR THE INHIBITION OF PROTEIN KINASE B | |
| ECSP13013024A (en) | 1,3-OXAZINES AS INHIBITORS OF BACE1 AND / OR BACE2 | |
| MX343160B (en) | Treatment of diseases. | |
| EA202191630A1 (en) | CHEMICALLY MODIFIED CONSTRUCTIONS FOR RNAi AND WAYS OF THEIR APPLICATION | |
| BR112019009953A2 (en) | substances targeted at various selected organs or tissues | |
| CY1120084T1 (en) | Oligonucleotide for the regulation of gene expression and their uses | |
| CY1124948T1 (en) | COMPOSITIONS WITH ANTI-CANCER ACTION | |
| AR113761A1 (en) | PEST CONTROL OF HEMIPTERS USING RNA MOLECULES | |
| BR112018010736A2 (en) | antisense oligonucleotides against il-34 and methods of using them | |
| AR098819A1 (en) | METHOD AND COMPOSITIONS FOR THE CONTROL OF PEST INSECTS IN PLANTS THROUGH THE SILENCING OF GENES OF THE FAMILY OF CHYTIN SYNTHEASE AND VITELOGENINE AS WELL AS ALTERNATIVELY FOR THE EXPRESSION OF THE GENE OF A CRY TOXIN | |
| AR108217A1 (en) | ADDRESSING LINKS CONSTITUTED BY OLIGOMERIC COMPOUNDS | |
| AR107824A1 (en) | ADDRESSING LINKS FOR THERAPEUTIC COMPOUNDS | |
| UY36399A (en) | AROMATIC COMPOUNDS REPLACED AND PHARMACEUTICAL COMPOSITIONS FOR THE SELF-TREATMENT AND REGENERATION OF THE FABRIC | |
| EA201891427A1 (en) | TARGET LIGANDS FOR THERAPEUTIC COMPOUNDS | |
| EA201891423A1 (en) | AIMING LIGANDS |